Navigation Links
Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
Date:6/16/2008

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced the appointment of Michael L. Kranda as president, chief executive officer and a member of the company's board of directors, effective June 16, 2008. Mr. Kranda succeeds John P. McLaughlin, who resigned as chief executive officer and member of the Anesiva board to pursue other business interests, while remaining a consultant to the company.

"Michael is the ideal person to lead Anesiva as it transitions from a drug development company to a commercially focused enterprise," said Rodney A. Ferguson, chairman of Anesiva's board. "He is a proven leader with extensive biotechnology experience and will be leading a great team here."

Mr. Kranda is a seasoned biopharmaceutical executive who brings two decades of commercial operating and corporate development experience to Anesiva. Most recently, he was Managing Director for biotechnology and life science investments at Vulcan, Inc. where he played an active role in the product, business development and financing activities of multiple portfolio companies. Before that, he was chief executive officer of Oxford GlycoSciences and led the transition of OGS from a biotech "tools" supply company to a leadership position in proteomics-based drug discovery and development. Prior to that, he served as president and chief operating officer and director at Immunex, where he built and managed sales, marketing, distribution, corporate development and manufacturing operations.

"With the upcoming commercial launch of Zingo(TM) and Adlea(TM) Phase 3 clinical milestones, Anesiva is poised to become a leader in the development and commercialization of novel pharmaceutical products for pain
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Genta,Incorporated (OTC Bulletin Board: GNTA) today announced financial results,for the ... year, the,Company has recorded significant milestones including the following:, ... -- Oral G4544 for bone disease completes single dose-trial in ... -- leading oral taxane and new clinical-stage ...
... expanded cholesterol test can help clinicians identify best treatment ... options for patients at risk of heart disease, ... announced it will be exhibiting its VAP,Cholesterol Test in booth ... 2008, the premier scientific meeting for internal,medicine. The annual meeting ...
... SHENZHEN, China, May 7 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical,International Limited ... of medical devices in China with a rapidly growing ... the,first quarter ended March 31, 2008., Highlights ... net revenues were RMB626.0 million (US$89.3 million), ...
Cached Biology Technology:Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 2Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 3Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 4Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 6Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 7Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 8Atherotech to Exhibit the VAP Test at Internal Medicine 2008 2Mindray Medical International Announces First Quarter 2008 Results 2Mindray Medical International Announces First Quarter 2008 Results 3Mindray Medical International Announces First Quarter 2008 Results 4Mindray Medical International Announces First Quarter 2008 Results 5Mindray Medical International Announces First Quarter 2008 Results 6Mindray Medical International Announces First Quarter 2008 Results 7Mindray Medical International Announces First Quarter 2008 Results 8Mindray Medical International Announces First Quarter 2008 Results 9Mindray Medical International Announces First Quarter 2008 Results 10Mindray Medical International Announces First Quarter 2008 Results 11Mindray Medical International Announces First Quarter 2008 Results 12Mindray Medical International Announces First Quarter 2008 Results 13Mindray Medical International Announces First Quarter 2008 Results 14Mindray Medical International Announces First Quarter 2008 Results 15Mindray Medical International Announces First Quarter 2008 Results 16Mindray Medical International Announces First Quarter 2008 Results 17Mindray Medical International Announces First Quarter 2008 Results 18
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... Chicago, November 23, 2010 Results of the world,s first ... or PrEP, were released online in the New England ... iPrEx, indicated an estimated 43.8% reduction of new HIV infections ... HIV, compared to those who took a placebo pill. ...
... how biological clocks adjust to having less sunlight in the winter ... shift work. Scientists studying the daily activity cycle in plants ... process that enables the plant,s genes to respond to the times ... of daylight in between. This system helps the plant to ...
... better tool to study how cells adhere to each other. ... stick together. Different kinds of cells have different kinds of ... focus on tens of thousands of them at a time ... but not on a single molecule. Sivasankar, an Iowa State ...
Cached Biology News:AIDS drug shown to prevent HIV in multinational trial of HIV-negative gay men 2AIDS drug shown to prevent HIV in multinational trial of HIV-negative gay men 3AIDS drug shown to prevent HIV in multinational trial of HIV-negative gay men 4Iowa State, Ames Lab researcher develops new way to study single biological molecules 2Iowa State, Ames Lab researcher develops new way to study single biological molecules 3
... 5 ml of DETACHaBEAD 19 polyclonal ... CD19 (Pan B). B cells ... and released with DETACHaBEAD CD19 are ... suitable for applications such as culturing ...
This Malachite Green Phosphate Detection Kit...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
...
Biology Products: